522-00-9 Usage
Description
ETHOPROPAZINE is a member of the phenothiazine class, specifically a derivative where the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. It is an antimuscarinic compound, which means it acts as an antagonist to the muscarinic acetylcholine receptors. This property makes it useful in the treatment of certain medical conditions.
Uses
Used in Pharmaceutical Industry:
ETHOPROPAZINE is used as an antiparkinsonian agent for the symptomatic treatment of Parkinson's disease. Its antimuscarinic properties help alleviate the symptoms associated with this neurodegenerative disorder.
ETHOPROPAZINE is also used as an anticholinergic agent, which means it can be employed to counteract the effects of acetylcholine, a neurotransmitter that plays a role in various bodily functions. This application can be beneficial in treating conditions where there is an overactivity of the parasympathetic nervous system, such as certain gastrointestinal disorders or urinary incontinence.
Safety Profile
Poison by ingestion,
subcutaneous, and intravenous routes. An
anticholinergic agent used to treat
Parkinson's dsease. When heated to
decomposition it emits very toxic fumes of
NOx and SOx.
Check Digit Verification of cas no
The CAS Registry Mumber 522-00-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,2 and 2 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 522-00:
(5*5)+(4*2)+(3*2)+(2*0)+(1*0)=39
39 % 10 = 9
So 522-00-9 is a valid CAS Registry Number.
InChI:InChI=1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3
522-00-9Relevant articles and documents
CONTROLLED RELEASE COMPOSITIONS AND METHODS FOR USING SAME
-
Page 30, (2010/02/06)
Pharmaceutical preparations adapted for mucosal delivery, preferably for nasal delivery, which can be easily and safely used over days to weeks with minimal side effects. The pharmaceutical preparations comprise microcapsules comprising at least one pharmaceutically active agent. The microcapsules provide controlled release of the pharmaceutically active agent. Cytotoxicity is avoided for cytotoxic pharmaceutically active agents and/or for cytotoxic dosages by one or more of the following: (a) manipulating the mucosal transport rate of the pharmaceutically active agent through the mucosal bodies to achieve a transport rate which is substantially the same as the controlled release rate, and/or (b) selecting only a most active and/or less cytotoxic enantiomer of the pharmaceutically active agent for use in the pharmaceutical preparation.
Stability of some phenothiazine free radicals.
Levy,Tozer,Tuck,Loveland
, p. 898 - 905 (2007/10/10)
-
